Standards for Follow-Up of Incidental Adrenal Findings

Abstract

Incidental adrenal findings, also known as adrenal incidentalomas, have become increasingly prevalent with the widespread use of cross-sectional imaging. This review aims to provide a comprehensive, evidence-based overview of the standards for follow-up of such findings, integrating recent guideline recommendations, clinical risk stratification, diagnostic pathways, and management options. The discussion highlights practical implications for clinicians, focusing on the identification of clinically significant lesions, exclusion of malignancy and hormonally active tumors, and the importance of individualized patient care. Mechanistic insights into adrenal tumor biology and emerging diagnostic and therapeutic advances are presented to inform optimal clinical decision-making.

Introduction

Incidental adrenal findings refer to adrenal masses detected unintentionally during imaging performed for unrelated indications. The increased utilization of abdominal computed tomography (CT) and magnetic resonance imaging (MRI) has led to a rise in the detection of such lesions, necessitating clear standards for evaluation and follow-up. Most adrenal incidentalomas are benign, nonfunctioning adenomas, but a minority may be hormonally active or malignant, warranting careful assessment. This article reviews the clinical approach to incidental adrenal findings, emphasizing the latest evidence and guideline-based recommendations for follow-up, risk stratification, and management.

Epidemiology / Disease Burden

The prevalence of adrenal incidentalomas ranges from 1% to 7% in the general population, increasing with age and reaching up to 10% in elderly patients. Most lesions are detected in individuals over 40 years of age, with no significant sex predilection. The growing burden of incidentalomas reflects not only advances in imaging technology but also the aging global population and increased comorbidities necessitating abdominal imaging. Despite their high prevalence, clinically significant findings—such as adrenocortical carcinoma or functional tumors—are rare, accounting for less than 1% of incidentalomas. The challenge lies in distinguishing benign, nonfunctioning lesions from those requiring intervention.

Pathophysiology

Adrenal incidentalomas encompass a spectrum of pathologies, including benign adenomas, myelolipomas, cysts, pheochromocytomas, and adrenocortical carcinomas. The underlying pathophysiology varies: nonfunctioning adenomas arise from clonal proliferation of cortical cells, often driven by somatic mutations (e.g., PRKACA, CTNNB1), while hormonally active tumors result from dysregulated steroidogenesis or catecholamine synthesis. Malignant transformation involves additional genetic and epigenetic alterations, with adrenocortical carcinoma demonstrating aggressive behavior and metastatic potential. Understanding the molecular mechanisms aids in risk stratification and the development of targeted therapies.

Risk Factors

Several factors increase the likelihood of clinically significant adrenal lesions. Large tumor size (>4 cm), rapid growth on serial imaging, atypical imaging features (e.g., irregular borders, high attenuation on unenhanced CT), and a history of malignancy heighten the risk of malignancy. Functional lesions are more common in patients with hypertension, diabetes, osteoporosis, or unexplained symptoms suggestive of hormonal excess. Genetic predispositions, such as MEN2 syndrome or familial pheochromocytoma-paraganglioma syndromes, should be considered in appropriate clinical contexts.

Clinical Features

Most patients with incidental adrenal lesions are asymptomatic. When clinical features are present, they may reflect hormonal excess: Cushing's syndrome (central obesity, proximal muscle weakness, hypertension), primary aldosteronism (hypertension, hypokalemia), or pheochromocytoma (paroxysmal hypertension, palpitations, diaphoresis, headaches). Features suggestive of malignancy include unexplained weight loss, abdominal pain, or symptoms related to metastatic disease. A thorough clinical evaluation is essential to identify subtle signs of functional or malignant lesions.

Diagnosis

The diagnostic approach to incidental adrenal findings involves a combination of biochemical and radiological assessment. Initial hormonal screening includes testing for cortisol excess (overnight dexamethasone suppression test), catecholamine excess (plasma free metanephrines or 24-hour urinary fractionated metanephrines), and aldosterone excess (plasma aldosterone-renin ratio in hypertensive patients with hypokalemia). Unenhanced CT is the imaging modality of choice for characterizing adrenal lesions, with attenuation <10 Hounsfield units suggesting benign adenoma. MRI with chemical shift imaging and contrast-enhanced studies may further differentiate indeterminate lesions. Biopsy is reserved for selected cases, particularly when metastatic disease is suspected and hormonal excess has been excluded.

Treatment & Management

Management of incidental adrenal findings is guided by lesion size, imaging characteristics, and biochemical profile. Nonfunctioning, benign-appearing lesions <4 cm generally require no intervention, with follow-up imaging at 6–12 months to assess stability. Functioning tumors and lesions with suspicious features warrant surgical resection, preferably by an experienced endocrine surgeon. In patients with contraindications to surgery or indeterminate lesions, multidisciplinary discussion and individualized follow-up protocols are recommended. Medical management may be indicated for functional lesions in select cases.

Recent Advances / Emerging Therapies

Recent advances include the development of radiomics and machine learning algorithms for improved risk stratification and noninvasive characterization of adrenal masses. Liquid biopsy techniques and circulating tumor markers are being investigated as adjuncts for malignancy detection. Targeted therapies, including tyrosine kinase inhibitors and immunotherapy, are under evaluation for advanced adrenocortical carcinoma. These innovations hold promise for refining diagnostic pathways and expanding treatment options for patients with clinically significant adrenal lesions.

Guideline Recommendations

Current guidelines from the European Society of Endocrinology (ESE), the American Association of Clinical Endocrinologists (AACE), and the Endocrine Society recommend a structured approach to incidental adrenal findings: comprehensive hormonal evaluation in all patients, imaging assessment for malignancy risk, and individualized follow-up based on initial findings. Nonfunctioning, benign-appearing lesions <4 cm may be followed with repeat imaging at 6–12 months; stable lesions generally require no further follow-up. Surgical referral is advised for lesions >4 cm, those with suspicious imaging features, or confirmed hormonal activity. Regular multidisciplinary team review is emphasized to ensure optimal patient outcomes.

Conclusion

The management of incidental adrenal findings requires adherence to evidence-based standards, thorough risk assessment, and individualized care. Advances in imaging, molecular diagnostics, and therapeutic modalities continue to refine clinical pathways and improve outcomes. Ongoing research and guideline updates are essential for optimizing the follow-up and treatment of patients with adrenal incidentalomas, minimizing unnecessary interventions while ensuring timely identification of clinically significant lesions.